Background: Soft-tissue sarcoma (sts) represents a rare group of mesenchymal neoplasms comprising more than 50 heterogeneous subtypes. Great efforts have been made to increase the understanding of the treatment of advanced sts (unresectable or metastatic disease). We set out to determine whether outcomes for patients with advanced sts have improved over time and to assess the current evidence for systemic therapy. Methods: In a scoping review, we evaluated the contemporary evidence for systemic treatment of advanced sts in adults (>18 years of age). Phase i, ii, and iii studies of systemic therapy for advanced sts published in the English language were included. After abstract and full-text review of seventy-seven studies, sixty-two trials met the inclusion criteria. Results: The number of clinical trials conducted and published in advanced sts has increased over the last 30 years. Although median overall survival has increased, attempts at improving first-line therapy through dose intensification, doublet chemotherapy, or alternative backbones have not been successful. The optimal therapy beyond anthracyclines remains a challenge, especially given the heterogeneity that grouping multiple sts subtypes within clinical trials creates. However, increasing numbers of agents are being studied, and several studies had shown isolated benefit in progression-free or overall survival. Summary: First-line systemic therapy with an anthracycline remains the standard of care for advanced sts. However, choice of subsequent therapy beyond anthracyclines remains challenging. Novel systemic therapies, use of molecular diagnostics to direct therapy, subtype-specific trials, and learnings from real-world retrospective data are all important for improving outcomes in patients with advanced sts. 2020 Multimed Inc.
Background: Soft-tissue sarcoma (sts) represents a rare group of mesenchymal neoplasms comprising more than 50 heterogeneous subtypes. Great efforts have been made to increase the understanding of the treatment of advanced sts (unresectable or metastatic disease). We set out to determine whether outcomes for patients with advanced sts have improved over time and to assess the current evidence for systemic therapy. Methods: In a scoping review, we evaluated the contemporary evidence for systemic treatment of advanced sts in adults (>18 years of age). Phase i, ii, and iii studies of systemic therapy for advanced sts published in the English language were included. After abstract and full-text review of seventy-seven studies, sixty-two trials met the inclusion criteria. Results: The number of clinical trials conducted and published in advanced sts has increased over the last 30 years. Although median overall survival has increased, attempts at improving first-line therapy through dose intensification, doublet chemotherapy, or alternative backbones have not been successful. The optimal therapy beyond anthracyclines remains a challenge, especially given the heterogeneity that grouping multiple sts subtypes within clinical trials creates. However, increasing numbers of agents are being studied, and several studies had shown isolated benefit in progression-free or overall survival. Summary: First-line systemic therapy with an anthracycline remains the standard of care for advanced sts. However, choice of subsequent therapy beyond anthracyclines remains challenging. Novel systemic therapies, use of molecular diagnostics to direct therapy, subtype-specific trials, and learnings from real-world retrospective data are all important for improving outcomes in patients with advanced sts. 2020 Multimed Inc.
Authors: Ian Judson; Jaap Verweij; Hans Gelderblom; Jörg T Hartmann; Patrick Schöffski; Jean-Yves Blay; J Martijn Kerst; Josef Sufliarsky; Jeremy Whelan; Peter Hohenberger; Anders Krarup-Hansen; Thierry Alcindor; Sandrine Marreaud; Saskia Litière; Catherine Hermans; Cyril Fisher; Pancras C W Hogendoorn; A Paolo dei Tos; Winette T A van der Graaf Journal: Lancet Oncol Date: 2014-03-05 Impact factor: 41.316
Authors: David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan Journal: Lancet Date: 2019-04-11 Impact factor: 79.321
Authors: H Gelderblom; J Y Blay; B M Seddon; M Leahy; I Ray-Coquard; S Sleijfer; J M Kerst; P Rutkowski; S Bauer; M Ouali; S Marreaud; R J H M van der Straaten; H-J Guchelaar; S D Weitman; P C W Hogendoorn; P Hohenberger Journal: Eur J Cancer Date: 2013-11-08 Impact factor: 9.162
Authors: V H Bramwell; H T Mouridsen; A Santoro; G Blackledge; R Somers; J Verwey; P Dombernowsky; M Onsrud; D Thomas; R Sylvester Journal: Eur J Cancer Clin Oncol Date: 1987-03
Authors: Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Suzanne George; Priscilla Merriam; Robert G Maki; Annick D Van den Abbeele; Jeffrey T Yap; Timothy Akhurst; David C Harmon; Gauri Bhuchar; Margaret M O'Mara; David R D'Adamo; Jeffrey Morgan; Gary K Schwartz; Andrew J Wagner; James E Butrynski; George D Demetri; Mary L Keohan Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Javier Martin-Broto; Antonio López Pousa; Ramón de Las Peñas; Xavier García Del Muro; Antonio Gutierrez; Javier Martinez-Trufero; Josefina Cruz; Rosa Alvarez; Ricardo Cubedo; Andrés Redondo; Joan Maurel; Juan A Carrasco; José A López-Martin; Ángeles Sala; José Andrés Meana; Rafael Ramos; Jordi Martinez-Serra; José A Lopez-Guerrero; Isabel Sevilla; Carmen Balaña; Ángeles Vaz; Ana De Juan; Regina Alemany; Andrés Poveda Journal: J Clin Oncol Date: 2016-05-16 Impact factor: 44.544
Authors: Thomas Gp Grünewald; Marta Alonso; Sofia Avnet; Ana Banito; Stefan Burdach; Florencia Cidre-Aranaz; Gemma Di Pompo; Martin Distel; Heathcliff Dorado-Garcia; Javier Garcia-Castro; Laura González-González; Agamemnon E Grigoriadis; Merve Kasan; Christian Koelsche; Manuela Krumbholz; Fernando Lecanda; Silvia Lemma; Dario L Longo; Claudia Madrigal-Esquivel; Álvaro Morales-Molina; Julian Musa; Shunya Ohmura; Benjamin Ory; Miguel Pereira-Silva; Francesca Perut; Rene Rodriguez; Carolin Seeling; Nada Al Shaaili; Shabnam Shaabani; Kristina Shiavone; Snehadri Sinha; Eleni M Tomazou; Marcel Trautmann; Maria Vela; Yvonne Mh Versleijen-Jonkers; Julia Visgauss; Marta Zalacain; Sebastian J Schober; Andrej Lissat; William R English; Nicola Baldini; Dominique Heymann Journal: EMBO Mol Med Date: 2020-10-13 Impact factor: 12.137
Authors: Sébastien Perreault; Rose Chami; Rebecca J Deyell; Dina El Demellawy; Benjamin Ellezam; Nada Jabado; Daniel A Morgenstern; Aru Narendran; Poul H B Sorensen; Jonathan D Wasserman; Stephen Yip Journal: Curr Oncol Date: 2021-01-09 Impact factor: 3.677